検索
ProQR Therapeutics NV
PRQRウォッチリストに追加
1.810USD
+0.060+3.43%
終値 07/02, 13:00（ET）15分遅れの株価
194.96M時価総額
損失額直近12ヶ月PER
詳細情報 ProQR Therapeutics NV 企業名
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
ProQR Therapeutics NVの企業情報
企業コードPRQR
会社名ProQR Therapeutics NV
上場日Sep 18, 2014
最高経営責任者「CEO」de Boer (Daniel Anton)
従業員数166
証券種類Ordinary Share
決算期末Sep 18
本社所在地Zernikedreef 9
都市LEIDEN
証券取引所NASDAQ OMX - NASDAQ BASIC
国Netherlands
郵便番号2333 CK
電話番号31881667000
ウェブサイトhttps://www.proqr.com/
企業コードPRQR
上場日Sep 18, 2014
最高経営責任者「CEO」de Boer (Daniel Anton)
ProQR Therapeutics NVの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
Ms. Alison F. Lawton
Ms. Alison F. Lawton
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Theresa M. Heggie
Ms. Theresa M. Heggie
Non-Executive Director
Non-Executive Director
--
--
Ms. Sarah Kiely
Ms. Sarah Kiely
Vice President - Investor Relations and Corporate Communications
Vice President - Investor Relations and Corporate Communications
--
--
Ms. Sheila Sponselee
Ms. Sheila Sponselee
Chief People and Operations Officer
Chief People and Operations Officer
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Gerard Platenburg, Ph.D.
Mr. Gerard Platenburg, Ph.D.
Chief Scientific Officer, Executive Director
Chief Scientific Officer, Executive Director
824.39K
--
Mr. Dinko Valerio, Ph.D.
Mr. Dinko Valerio, Ph.D.
Non-Executive Director
Non-Executive Director
725.69K
--
Mr. Bart Filius
Mr. Bart Filius
Non-Executive Independent Director
Non-Executive Independent Director
150.00K
--
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
61.54K
--
Mr. Daniel Anton de Boer
Mr. Daniel Anton de Boer
Chief Executive Officer, Founder, Executive Director
Chief Executive Officer, Founder, Executive Director
--
--
Mr. Rene K. Beukema
Mr. Rene K. Beukema
Chief Corporate Development Officer, General Counsel, Executive Director
Chief Corporate Development Officer, General Counsel, Executive Director
--
--
よくある質問
ProQR Therapeutics NVの上位5名の株主は誰ですか？
ProQR Therapeutics NVの上位5名の株主は以下のとおりです。Mr. Gerard Platenburg, Ph.D.
ProQR Therapeutics NV（PRQR）の株式を保有している機関の数はいくつですか？
2026Q1時点で、ProQR Therapeutics NVの株式を保有している機関は122社あり、保有株式の総市場価値は約38.34Mで、全体の36.39%を占めています。2025Q4と比較して、機関の持ち株は-5670621.00増加しています。